Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 137,300 shares, an increase of 8.3% from the December 31st total of 126,800 shares. Based on an average trading volume of 33,600 shares, the days-to-cover ratio is currently 4.1 days. Approximately 2.3% of the company’s stock are sold short.
Aytu BioPharma Stock Performance
Shares of NASDAQ:AYTU traded down $0.03 on Monday, hitting $1.64. 7,334 shares of the company were exchanged, compared to its average volume of 21,320. The firm has a market capitalization of $10.09 million, a P/E ratio of -1.33 and a beta of -1.45. Aytu BioPharma has a 1-year low of $1.30 and a 1-year high of $3.45. The stock’s 50 day moving average price is $1.62 and its 200 day moving average price is $2.07. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35.
Hedge Funds Weigh In On Aytu BioPharma
An institutional investor recently raised its position in Aytu BioPharma stock. Dimensional Fund Advisors LP grew its position in Aytu BioPharma, Inc. (NASDAQ:AYTU – Free Report) by 54.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,551 shares of the company’s stock after buying an additional 8,311 shares during the period. Dimensional Fund Advisors LP owned 0.39% of Aytu BioPharma worth $69,000 as of its most recent SEC filing. 33.49% of the stock is currently owned by institutional investors and hedge funds.
About Aytu BioPharma
Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.
Recommended Stories
- Five stocks we like better than Aytu BioPharma
- Earnings Per Share Calculator: How to Calculate EPS
- These Are the Dividend Stocks Insiders Bought in January
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
- What is a Stock Market Index and How Do You Use Them?
- Apple Comes Out From Behind to Emerge as An AI-Services Leader
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
